Doms № 1 -2022

Doms № 2 -2022 (67-74 p)

Long-term results of treatment of patients with type 2 diabetes with sodium-glucose cotransporter-2 (sglt2) inhibitors
Kravchun N.O., Zemlyanitsyna O.V., Dunaeva I.P., Dorosh O.G. 


Sodium-glucose cotransporter-2 (SGLT2) inhibitors are medications that protect against cardiovascular diseases and mortality in patients with diabetes mellitus (DM) type 2 of different age groups with the presence of comorbid pathology and numerous complications. Huge data of results achieved may vary in different cases, but already existing data testify the importance and necessity of prescribing such innovative medications as SGLT2. The aim of the study. Tracking the long-term results of the combined therapy of dapagliflozin and metformin on the state of carbohydrate, lipid and protein metabolism, indicators of liver function in patients with type 2 diabetes, representatives of the Ukrainian population.

Materials and methods: 60 patients with type 2 diabetes took part in the study, 34 of them were men and 26 — women. The average age of the patients was (57.52 ± 0.96) years. 39 (65.0%) patients had diabetes of moderate severity, hundred, in 21 (35.0%) – of severe diabetes. Insulin dependence was observed in 11 patients (18.3%). Therapy of patients with type 2 diabetes included adherence to dietary recommendations, namely, nutritional correction and prescription of tableted oral hypoglycemic agents: dpagliflozin in a daily dose 10 mg and metformin in a daily dose of 1,500 to 2,000 mg, in 11 patients along with tableted sugar-lowering insulin was additionally prescribed as a general medication. Levels were determined for all patients of carbohydrate, lipid and protein metabolism, indicators of liver function.

The results. Long-term treatment with dapagliflozin in combination with metformin in patients with type 2 diabetes showed its effectiveness. An improvement in the indicators of carbohydrate, lipid and protein metabolism was found, indicators of liver tests and liver synthetic function in patients with type 2 diabetes, representatives of Ukrainian population.

Conclusions. The expediency of using the combination of dapagliflozin in combination with with metformin as hypoglycemic therapy for a long period in patients with type 2 diabetes.

Keywords: type 2 diabetes, Sodium-glucose cotransporter-2 (SGLT2) inhibitors, treatment

  1. Consensus statement by the american association of clinical endocrinologists and american college of endocrinology on the comprehensive type 2 diabetes management algo- rithm – 2020 executive summary / J. G. Alan, H. Yehuda, G. Grunberger et al. Endocr Pract. 2020;26 (1): 107-139. doi: 10.4158/CS-2019-0472.
  2. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis / K. I. Birkeland, M. E. Jørgensen, B. Carstensen et al. Lan- cet Diabetes Endocrinol. 2017;5(9):709-717. doi: 10.1016/ S2213-8587(17)30258-9.
  3. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl pep- tidase-4 inhibitor therapy: A multinational observational study / F. Persson, T. Nyström, M. E. Jørgensen et al. Diabetes Obes Metab. 2018; 20(2):344-351. doi: 10.1111/dom.13077.
  4. Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study / M. Kosiborod, C.S.P. Lam, S. Kohsaka et al. J Am Coll Cardiol. 2018;12: 71(23):2628-2639. doi: 10.1016/j. jacc.2018.03.009.
  5. SGLT2 inhibitors and cardiovascular outcomes: Do they differ or there is a class effect? New insights from the EMPA- REG OUTCOME trial and the CVD-REAL Study / G. Kyria- kos, L. V. Quiles-Sanchez, A. Garmpi et al. Curr Cardiol Rev. 2019; 29: 12-24. doi: 10.2174/1573403X15666190730094215.
  6. SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mel- litus: A Comprehensive and Critical Review of the Literature / K. Imprialos, C. Faselis, C. Boutari et al. Curr Pharm Des. 2017; 23(10):1510-1521. doi: 10.2174/1381612823666170 124123927.
  7. Vallon V., Thomson S. C. Diabetes mellitus: Cardiovascular and renal benefits of SGLT2 inhibition: insights from CAN- VAS. Nat Rev Nephrol. 2017;13(9):517-518. doi: 10.1038/ nrneph.2017.113
  8. Wang J., Xu Y. Letter by Wang and Xu Regarding Article, “Age at Diagnosis of Type 2 Diabetes Mellitus and Asso- ciations With Cardiovascular and Mortality Risks”. Circula- tion. 2019;15:140(16):e722-e723. doi: 10.1161/CIRCULA- TIONAHA.119.041840.
  9. Strain W. D., Paldánius P. M .Diabetes, cardiovascular disease and the microcirculation. Cardiovasc Diabetol. 2018;18:17(1):57. doi: 10.1186/s12933-018-0703-2.
  10. Petrie J. R., Guzik T. J., Touyz R. M. Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. Can J Cardiol. 2018;34(5):575-584. doi: 10.1016/j.cjca.2017.12.005.
  11. Wu L., Gunton J. E. The Changing Landscape of Pharmacotherapy for Diabetes Mellitus: A Review of Cardiovascular Outcomes. Int J Mol Sci. 2019; 20(23):5853. doi: 10.3390/ ijms20235853.
  12. Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study / M. Kosiborod, K. I. Birkeland, M. A. Cavender et al. Diabetes Obes Metab. 2018;20(8):1983-1987. doi: 10.1111/dom.13299.
  13. Association of obesity with heart failure outcomes in 11 Asian regions: A cohort study / C. Chandramouli, W. T . Tay, N. S. Bamadhaj. et al. PLoS Med. 2019; 16(9):e1002916. doi: 10.1371/journal.pmed.1002916.
  14. Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus / K. Iglay, H. Hannachi, P. Joseph Howie et al. Curr Med Res Opin. 2016;32(7):1243-52. doi: 10.1185/03007995.2016.1168291.
  15. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors) / M. Kosiborod, M. A. Cavender, A. Z. Fu et al. Circulation. 2017;136(3):249-259. doi: 10.1161/CIRCULA- TIONAHA.117.029190.
  16. SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL / M. A. Cavender, A. Norhammar, K. I. Birkeland et al. J Am Coll Cardiol. 2018;71(22):2497-2506. doi: 10.1016/j.jacc.2018.01.085.
  17. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient I-amino acid-defined diet in rats / Y. Hayashizaki- Someya, E. Kurosaki, T. Takasu et al. Eur J Pharmacol. 2015; 754: 19-24.
  18. Effectiveness of dapagliflozin in nonalcoholic fatty liver disease in type 2 diabetes patients compared to sitagliptin and pioglitazone/ A. Koutsovasilis, A. Sotiropoulos, E. Blesta et al. EASD Meeting. Abstract, 11-15 September 2017, Lis- bon, Portugal. URL: home.html#! resources/effectiveness-of-dapagliflozin-in- nonalcoholic-fatty-liver-disease-in-type-2-diabetes-patients- compared-to-sitagliptin-and-pioglitazone.
  19. Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study / H. Tobita, S. Sato, T. Miyake et al. Current Therapeutic Research. 2017;87: 13-19.
  20. Zemlyanіcina O. V. Antifіbrotichnij efekt kombіnovanoї terapії dapaglіflozinom і metformіnom u pacієntіv іz cukrovim dіabetom 2 tipu ta nealkogol’noyu zhirovoyu hvo- roboyu pechіnki. Probl. endokrin. patologії. 2019;2: 27-33. [in Ukraine]. doi:
  21. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial / S. D. Wiviott, I. Raz, M. P. Bonaca et al. Am Heart J. 2018;200:83- 89. doi: 10.1016/j.ahj.2018.01.012.
  22. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial / O. Mosenzon, S. D. Wiviott, A. Cahn et al. Lancet Diabetes Endocrinol. 2019;7(8):606-617. doi: 10.1016/S2213-8587(19)30180-9.
  23. Cardiorenal Outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME Trials: A Systematic Review / A. Y. Kluger, K. M. Tecson, C. M. Barbin et al. Rev Cardiovasc Med. 2018;19 (2):41-49. doi: 10.31083/j.rcm.2018.02.907.
  24. DECLARE-TIMI 58: Participants’ baseline characteristics / I. Raz, O. Mosenzon, M. P. Bonaca et al. Diabetes Obes Metab. 2018;20(5):1102-1110. doi: 10.1111/dom.13217.
  25. Sokolova L. K. Cukrovij dіabet і kardіovaskulyarnij rizik: vibіr optimal’noї cukroznizhuyuchoї terapії. Zdorov’ya Ukraїni. 2019;1 (45): 27-28.
  26. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINEHF trial / M. E. Nassif, S. Windsor, F. Tang et al. Circulation. 2019; 140: 1463-1476.
  27. Williams D. M., Evans M. Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver? Diabetes Ther. 2020; 11: 2207-2219. https://doi. org/10.1007/s13300-020-00911-0.
  28. Williams D. M., Evans M. Are SGLT-2 inhibitors the future of heart failure treatment? The EMPEROR-Preserved and EMPEROR-Reduced Trials. Diabetes Ther. 2020;11:1925-34.
  29. Packer M., Butler J., Filippatos G. S. et al. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. Eur J Heart Fail. 2019; 21:1270-1278. doi:10.1002/ejhf.1536.
  30. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR- Preserved Trial / S. D. Anker, J. Butler, G. S. Filippatos et al. Eur J Heart Fail. 2019; 21: 1279-1287. doi:10.1002/ejhf.1596.
  31. Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective / F. Savira, B. H. Wang, A. R. Kompa et al. Eur J Prev Cardiol. 2020.
  32. Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis / C. Arnott, Q. Li, A. Kang et al. J Am Heart Assoc. 2020; 9 (3): e014908. doi: 10.1161/JAHA.119.014908.